肿瘤伴随诊断市场、份额、规模、趋势、行业分析报告：按产品、按技术、按疾病类型、按最终用户、按地区、按细分市场、预测，2023-2032 年

根据 Polaris Market Research 的一项新研究，到 2032 年，全球肿瘤伴随诊断市场预计将达到 105.7 亿美元。 该报告提供了对当前市场动态的详细洞察，并对未来市场成长进行了分析。

向以患者为中心的医疗保健的转变正在为伴随诊断创造有利的环境。 这些工具使医疗保健提供者能够制定量身定制的治疗计划，最大限度地减少副作用并优化患者的治疗结果。 这种以病人为中心的方法在医疗保健环境中越来越受到重视。 患者对伴随诊断的认识不断提高，为扩大采用伴随诊断提供了机会。 让患者参与治疗并向他们提供有关这些诊断的好处的资讯将推动市场成长。

伴随诊断提供了一条实现更具成本效益的医疗保健途径。 透过减少无效治疗的使用并最大限度地减少住院和併发症，这些工具有助于控制医疗费用。 市场受益于旨在发现与各种癌症类型相关的新生物标记和遗传标记的持续研究工作。 这些发现扩大了伴随诊断的应用，并为市场成长提供了新的机会。

新兴国家拥有庞大的成长机会。 由于医疗基础设施的改善和意识的提高，预计这些地区伴随诊断的采用将显着增加。 远距医疗和远距诊断在医疗保健领域的扩展提供了改善伴随诊断测试的机会。 这一趋势扩大了市场基础，特别是在服务不足和偏远地区。

诊断技术的创新，包括液体活检和新一代定序，为更准确、更全面的伴随诊断提供了机会。 这些创新将提高诊断准确性并扩大测试能力。

肿瘤伴随诊断市场报告亮点

由于癌症发生率上升、世界人口老化以及精准医疗的进步，该产品领域将在2022年占据较大份额

免疫组织化学因其广泛用于生物标记检测、亚型分型和治疗指导而成为最大的细分领域。

预计乳癌领域将在预测期内出现显着增长，这主要是由于标靶治疗和监管支持的采用增加。

到 2022 年，医院细分市场将占据最大的市场收入份额，主要得益于早期检测和诊断、治疗监测以及以患者为中心的护理

由于个人化医疗、监管框架、合作伙伴关係和协作研究的兴起，北美地区在 2022 年占据了大部分市场份额。

目录

第一章简介

第 2 章执行摘要

第三章研究方法

第 4 章全球肿瘤伴随诊断市场洞察

• 肿瘤学伴随诊断 - 产业概况
• 肿瘤伴随诊断市场动态
  • 推动者和机会
    • 癌症病例不断增加、癌症标靶治疗的可用性不断扩大以及精准医疗取得进展
    • 日益关注个人化医疗
  • 抑制因素和挑战
    • 监理问题与审批流程
• 杵分析
• 肿瘤伴随诊断产业的趋势
• 价值链分析
• COVID-19 感染的影响分析

第 5 章全球肿瘤伴随诊断市场（依技术）

• 主要发现
• 简介
• 免疫组织化学
• 次世代定序
• 聚合□炼式反应
• 其他

第 6 章全球肿瘤伴随诊断市场（以报价）

• 主要发现
• 简介
• 产品
• 服务

第 7 章依疾病类型划分的全球肿瘤伴随诊断市场

• 主要发现
• 简介
• 黑色素瘤
• 乳癌
• 大肠直肠癌
• 白血病
• 摄护腺癌
• 其他

第 8 章全球肿瘤伴随诊断市场（按最终用户）

• 主要发现
• 简介
• 医院
• 诊断实验室
• 其他

第 9 章按地区划分的全球肿瘤伴随诊断市场

• 主要发现
• 简介
  • 2019-2032 年肿瘤伴随诊断市场评估，地区
• 肿瘤伴随诊断市场 - 北美
  • 北美：肿瘤伴随诊断市场（按技术），2019-2032 年
  • 北美：肿瘤伴随诊断市场，按最终用户划分，2019-2032 年
  • 北美：2019-2032 年肿瘤伴随诊断市场（依产品划分）
  • 北美：肿瘤伴随诊断市场（依疾病类型），2019-2032 年
  • 肿瘤伴随诊断市场 - 美国
  • 肿瘤伴随诊断市场 - 加拿大
• 肿瘤伴随诊断市场 - 欧洲
  • 欧洲：肿瘤伴随诊断市场（按技术），2019-2032 年
  • 欧洲：肿瘤伴随诊断市场，依最终使用者划分，2019-2032 年
  • 欧洲：2019-2032 年肿瘤伴随诊断市场（依产品划分）
  • 欧洲：肿瘤伴随诊断市场（依疾病类型），2019-2032 年
  • 肿瘤伴随诊断市场 - 英国
  • 肿瘤伴随诊断市场 - 法国
  • 肿瘤伴随诊断市场 - 德国
  • 肿瘤伴随诊断市场 - 义大利
  • 肿瘤伴随诊断市场 - 西班牙
  • 肿瘤伴随诊断市场 - 荷兰
  • 肿瘤伴随诊断市场 - 俄罗斯
• 肿瘤伴随诊断市场 - 亚太地区
  • 亚太地区：肿瘤伴随诊断市场（按技术），2019-2032 年
  • 亚太地区：肿瘤伴随诊断市场，依最终用户划分，2019-2032 年
  • 亚太地区：肿瘤伴随诊断市场（按产品划分），2019-2032 年
  • 亚太地区：2019-2032 年肿瘤伴随诊断市场（依疾病类型）
  • 肿瘤伴随诊断市场 - 中国
  • 肿瘤伴随诊断市场 - 印度
  • 肿瘤伴随诊断市场 - 日本
  • 肿瘤伴随诊断市场 - 马来西亚
  • 肿瘤伴随诊断市场 - 印度尼西亚
  • 肿瘤伴随诊断市场 - 韩国
• 肿瘤伴随诊断市场 - 中东和非洲
  • 中东和非洲：肿瘤伴随诊断市场（按技术），2019-2032 年
  • 中东和非洲：肿瘤伴随诊断市场，按最终用户划分，2019-2032 年
  • 中东与非洲：2019-2032 年肿瘤伴随诊断市场（依产品划分）
  • 中东和非洲：肿瘤伴随诊断市场（按疾病类型），2019-2032 年
  • 肿瘤伴随诊断市场 - 沙乌地阿拉伯
  • 肿瘤伴随诊断市场 - 南非
  • 肿瘤伴随诊断市场 - 以色列
  • 肿瘤伴随诊断市场 - 阿联酋
• 肿瘤伴随诊断市场 - 拉丁美洲
  • 拉丁美洲：肿瘤伴随诊断市场（按技术），2019-2032 年
  • 拉丁美洲：肿瘤伴随诊断市场，按最终用户划分，2019-2032 年
  • 拉丁美洲：肿瘤伴随诊断市场，依报价，2019-2032 年
  • 拉丁美洲：2019-2032 年肿瘤伴随诊断市场（依疾病类型）
  • 肿瘤伴随诊断市场 - 墨西哥
  • 肿瘤伴随诊断市场 - 巴西
  • 肿瘤伴随诊断市场 - 阿根廷

第10章竞争态势

• 扩张与收购分析
  • 放大
  • 收购
• 伙伴关係/协作/协议/揭露

第十一章公司简介

• Abbott Laboratories
• Agilent Technologies
• Bio-Rad Laboratories
• Biocartis
• Exact Sciences
• Genedrive
• Genomic Health
• Guardant Health
• Illumina
• Invivoscribe
• Myriad Genetics
• QIAGEN
• Roche Diagnostics
• Sysmex Corporation
• Thermo Fisher Scientific

The global oncology companion diagnostic market size is expected to reach USD 10.57 billion by 2032, according to a new study by Polaris Market Research. The report "Oncology Companion Diagnostic Market Share, Size, Trends, Industry Analysis Report, By Offering (Product, Services); By Technology; By Disease Type; By End User; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The shift towards patient-centered healthcare has created a favorable environment for companion diagnostics. These tools enable healthcare providers to design tailored treatment plans, minimizing side effects and optimizing patient outcomes. This patient-centric approach is increasingly valued in the healthcare landscape. The rising awareness of companion diagnostics among patients provides an opportunity for increased adoption. Engaging patients in their care and empowering them with information about the benefits of these diagnostics drives market growth.

Companion diagnostics offer a route to more cost-effective healthcare. By reducing the use of ineffective therapies and minimizing the occurrence of hospitalizations and complications, these tools contribute to healthcare cost containment. The market benefits from ongoing research efforts aimed at discovering new biomarkers and genetic markers associated with various cancer types. These discoveries expand the applications of companion diagnostics, opening up new opportunities for market growth.

Emerging economies offer a significant growth opportunity. As these regions improve healthcare infrastructure and increase awareness, the adoption of companion diagnostics is poised for substantial growth. The expansion of telemedicine and remote diagnostics in healthcare presents opportunities to increase access to companion diagnostic testing. This trend, particularly relevant in underserved or remote areas, broadens the market's reach.

The ongoing innovations in diagnostic technologies, including liquid biopsies and next-generation sequencing, present opportunities for more accurate and comprehensive companion diagnostics. These innovations can lead to greater diagnostic precision and expanded testing capabilities.

Oncology Companion Diagnostic Market Report Highlights

Product segment held a significant share in 2022, owing to growing cancer prevalence, global aging population, and advancements in precision medicine

Immunohistochemistry emerged as the largest segment on account of its wide use in biomarker detection, subtype classification, and treatment guidance

The breast cancer segment is expected to experience significant growth during the forecast period, which is mainly driven by its growing adoption of targeted therapies and regulatory support

Hospitals segment held the maximum market revenue share in 2022, mainly for early detection and diagnosis, treatment monitoring, and patient-centric care

North America region dominated the market with majority share in 2022, owing to the rise of personalized medicine, regulatory framework, and partnerships and collaborations

The global key market players include: Abbott Laboratories, Agilent Technologies, Illumina, Invivoscribe, Roche Diagnostics, Sysmex Corporation, and Thermo Fisher Scientific, among others

Polaris Market Research has segmented the Oncology Companion Diagnostic market report based on offering, technology, disease type, end user, and region:

Oncology Companion Diagnostic, Offering Outlook (Revenue - USD Billion, 2019 - 2032)

• Product
• Services

Oncology Companion Diagnostic, Technology Outlook (Revenue - USD Billion, 2019 - 2032)

• Immunohistochemistry
• Next-Generation Sequencing
• Polymerase Chain Reaction
• Others

Oncology Companion Diagnostic, Disease Type Outlook (Revenue - USD Billion, 2019 - 2032)

• Melanoma
• Breast Cancer
• Colorectal Cancer
• Leukaemia
• Prostate Cancer
• Others

Oncology Companion Diagnostic, End User Outlook (Revenue - USD Billion, 2019 - 2032)

• Hospitals
• Diagnostic Labs
• Others

Oncology Companion Diagnostic, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Latin America
• Argentina
• Brazil
• Mexico
• Middle East & Africa
• UAE
• Saudi Arabia
• Israel
• South Africa

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Oncology Companion Diagnostic Market Insights

• 4.1. Oncology Companion Diagnostic - Industry Snapshot
• 4.2. Oncology Companion Diagnostic Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Rising cancer cases, growing availability of targeted cancer therapies, and precision medicine advancements
    • 4.2.1.2. Growing emphasis on personalized medicine
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. Regulatory challenges and approval processes
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTLE Analysis
• 4.5. Oncology Companion Diagnostic Industry Trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Oncology Companion Diagnostic Market, by Technology

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• 5.3. Immunohistochemistry
  • 5.3.1. Global Oncology Companion Diagnostic Market, by Immunohistochemistry, by Region, 2019-2032 (USD Billion)
• 5.4. Next-Generation Sequencing
  • 5.4.1. Global Oncology Companion Diagnostic Market, by Next-Generation Sequencing, by Region, 2019-2032 (USD Billion)
• 5.5. Polymerase Chain Reaction
  • 5.5.1. Global Oncology Companion Diagnostic Market, by Polymerase Chain Reaction, by Region, 2019-2032 (USD Billion)
• 5.6. Others
  • 5.6.1. Global Oncology Companion Diagnostic Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Oncology Companion Diagnostic Market, by Offering

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• 6.3. Product
  • 6.3.1. Global Oncology Companion Diagnostic Market, by Product, by Region, 2019-2032 (USD Billion)
• 6.4. Services
  • 6.4.1. Global Oncology Companion Diagnostic Market, by Services, by Region, 2019-2032 (USD Billion)

7. Global Oncology Companion Diagnostic Market, by Disease Type

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Oncology Companion Diagnostic Market, by Disease Type, 2019-2032 (USD Billion)
• 7.3. Melanoma
  • 7.3.1. Global Oncology Companion Diagnostic Market, by Melanoma, by Region, 2019-2032 (USD Billion)
• 7.4. Breast Cancer
  • 7.4.1. Global Oncology Companion Diagnostic Market, by Breast Cancer, by Region, 2019-2032 (USD Billion)
• 7.5. Colorectal Cancer
  • 7.5.1. Global Oncology Companion Diagnostic Market, by Colorectal Cancer, by Region, 2019-2032 (USD Billion)
• 7.6. Leukaemia
  • 7.6.1. Global Oncology Companion Diagnostic Market, by Leukaemia, by Region, 2019-2032 (USD Billion)
• 7.7. Prostate Cancer
  • 7.7.1. Global Oncology Companion Diagnostic Market, by Prostate Cancer, by Region, 2019-2032 (USD Billion)
• 7.8. Others
  • 7.8.1. Global Oncology Companion Diagnostic Market, by Others, by Region, 2019-2032 (USD Billion)

8. Global Oncology Companion Diagnostic Market, by End User

• 8.1. Key Findings
• 8.2. Introduction
  • 8.2.1. Global Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• 8.3. Hospitals
  • 8.3.1. Global Oncology Companion Diagnostic Market, by Hospitals, by Region, 2019-2032 (USD Billion)
• 8.4. Diagnostic Labs
  • 8.4.1. Global Oncology Companion Diagnostic Market, by Diagnostic Labs, by Region, 2019-2032 (USD Billion)
• 8.5. Others
  • 8.5.1. Global Oncology Companion Diagnostic Market, by Others, by Region, 2019-2032 (USD Billion)

9. Global Oncology Companion Diagnostic Market, by Geography

• 9.1. Key findings
• 9.2. Introduction
  • 9.2.1. Oncology Companion Diagnostic Market Assessment, By Geography, 2019-2032 (USD Billion)
• 9.3. Oncology Companion Diagnostic Market - North America
  • 9.3.1. North America: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • 9.3.2. North America: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • 9.3.3. North America: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • 9.3.4. North America: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.3.5. Oncology Companion Diagnostic Market - U.S.
    • 9.3.5.1. U.S.: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.3.5.2. U.S.: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.3.5.3. U.S.: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.3.5.4. U.S.: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.3.6. Oncology Companion Diagnostic Market - Canada
    • 9.3.6.1. Canada: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.3.6.2. Canada: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.3.6.3. Canada: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.3.6.4. Canada: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• 9.4. Oncology Companion Diagnostic Market - Europe
  • 9.4.1. Europe: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • 9.4.2. Europe: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • 9.4.3. Europe: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • 9.4.4. Europe: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.4.5. Oncology Companion Diagnostic Market - UK
    • 9.4.5.1. UK: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.4.5.2. UK: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.4.5.3. UK: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.4.5.4. UK: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.4.6. Oncology Companion Diagnostic Market - France
    • 9.4.6.1. France: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.4.6.2. France: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.4.6.3. France: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.4.6.4. France: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.4.7. Oncology Companion Diagnostic Market - Germany
    • 9.4.7.1. Germany: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.4.7.2. Germany: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.4.7.3. Germany: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.4.7.4. Germany: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.4.8. Oncology Companion Diagnostic Market - Italy
    • 9.4.8.1. Italy: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.4.8.2. Italy: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.4.8.3. Italy: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.4.8.4. Italy: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.4.9. Oncology Companion Diagnostic Market - Spain
    • 9.4.9.1. Spain: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.4.9.2. Spain: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.4.9.3. Spain: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.4.9.4. Spain: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.4.10. Oncology Companion Diagnostic Market - Netherlands
    • 9.4.10.1. Netherlands: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.4.10.2. Netherlands: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.4.10.3. Netherlands: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.4.10.4. Netherlands: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.4.11. Oncology Companion Diagnostic Market - Russia
    • 9.4.11.1. Russia: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.4.11.2. Russia.: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.4.11.3. Russia: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.4.11.4. Russia: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• 9.5. Oncology Companion Diagnostic Market - Asia Pacific
  • 9.5.1. Asia Pacific: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • 9.5.2. Asia Pacific: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • 9.5.3. Asia Pacific: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • 9.5.4. Asia Pacific: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.5.5. Oncology Companion Diagnostic Market - China
    • 9.5.5.1. China: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.5.5.2. China.: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.5.5.3. China: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.5.5.4. China: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.5.6. Oncology Companion Diagnostic Market - India
    • 9.5.6.1. India: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.5.6.2. India.: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.5.6.3. India: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.5.6.4. India: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.5.7. Oncology Companion Diagnostic Market - Japan
    • 9.5.7.1. Japan: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.5.7.2. Japan.: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.5.7.3. Japan: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.5.7.4. Japan: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.5.8. Oncology Companion Diagnostic Market - Malaysia
    • 9.5.8.1. Malaysia: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.5.8.2. Malaysia.: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.5.8.3. Malaysia: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.5.8.4. Malaysia: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.5.9. Oncology Companion Diagnostic Market - Indonesia
    • 9.5.9.1. Indonesia: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.5.9.2. Indonesia.: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.5.9.3. Indonesia: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.5.9.4. Indonesia: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.5.10. Oncology Companion Diagnostic Market - South Korea
    • 9.5.10.1. South Korea: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.5.10.2. South Korea.: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.5.10.3. South Korea: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.5.10.4. South Korea: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• 9.6. Oncology Companion Diagnostic Market - Middle East & Africa
  • 9.6.1. Middle East & Africa: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • 9.6.2. Middle East & Africa: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • 9.6.3. Middle East & Africa: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • 9.6.4. Middle East & Africa: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.6.5. Oncology Companion Diagnostic Market - Saudi Arabia
    • 9.6.5.1. Saudi Arabia: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.6.5.2. Saudi Arabia: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.6.5.3. Saudi Arabia: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.6.5.4. Saudi Arabia: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.6.6. Oncology Companion Diagnostic Market - South Africa
    • 9.6.6.1. South Africa: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.6.6.2. South Africa: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.6.6.3. South Africa: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.6.6.4. South Africa: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.6.7. Oncology Companion Diagnostic Market - Israel
    • 9.6.7.1. Israel: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.6.7.2. Israel: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.6.7.3. Israel: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.6.7.4. Israel: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.6.8. Oncology Companion Diagnostic Market - UAE
    • 9.6.8.1. UAE: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.6.8.2. UAE: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.6.8.3. UAE: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.6.8.4. UAE: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• 9.7. Oncology Companion Diagnostic Market - Latin America
  • 9.7.1. Latin America: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • 9.7.2. Latin America: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • 9.7.3. Latin America: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • 9.7.4. Latin America: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.7.5. Oncology Companion Diagnostic Market - Mexico
    • 9.7.5.1. Mexico: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.7.5.2. Mexico: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.7.5.3. Mexico: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.7.5.4. Mexico: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.7.6. Oncology Companion Diagnostic Market - Brazil
    • 9.7.6.1. Brazil: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.7.6.2. Brazil: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.7.6.3. Brazil: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.7.6.4. Brazil: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.7.7. Oncology Companion Diagnostic Market - Argentina
    • 9.7.7.1. Argentina: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.7.7.2. Argentina: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.7.7.3. Argentina: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.7.7.4. Argentina: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)

10. Competitive Landscape

• 10.1. Expansion and Acquisition Analysis
  • 10.1.1. Expansion
  • 10.1.2. Acquisitions
• 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

• 11.1. Abbott Laboratories
  • 11.1.1. Company Overview
  • 11.1.2. Financial Performance
  • 11.1.3. Product Benchmarking
  • 11.1.4. Recent Development
• 11.2. Agilent Technologies
  • 11.2.1. Company Overview
  • 11.2.2. Financial Performance
  • 11.2.3. Product Benchmarking
  • 11.2.4. Recent Development
• 11.3. Bio-Rad Laboratories
  • 11.3.1. Company Overview
  • 11.3.2. Financial Performance
  • 11.3.3. Product Benchmarking
  • 11.3.4. Recent Development
• 11.4. Biocartis
  • 11.4.1. Company Overview
  • 11.4.2. Financial Performance
  • 11.4.3. Product Benchmarking
  • 11.4.4. Recent Development
• 11.5. Exact Sciences
  • 11.5.1. Company Overview
  • 11.5.2. Financial Performance
  • 11.5.3. Product Benchmarking
  • 11.5.4. Recent Development
• 11.6. Genedrive
  • 11.6.1. Company Overview
  • 11.6.2. Financial Performance
  • 11.6.3. Product Benchmarking
  • 11.6.4. Recent Development
• 11.7. Genomic Health
  • 11.7.1. Company Overview
  • 11.7.2. Financial Performance
  • 11.7.3. Product Benchmarking
  • 11.7.4. Recent Development
• 11.8. Guardant Health
  • 11.8.1. Company Overview
  • 11.8.2. Financial Performance
  • 11.8.3. Product Benchmarking
  • 11.8.4. Recent Development
• 11.9. Illumina
  • 11.9.1. Company Overview
  • 11.9.2. Financial Performance
  • 11.9.3. Product Benchmarking
  • 11.9.4. Recent Development
• 11.10. Invivoscribe
  • 11.10.1. Company Overview
  • 11.10.2. Financial Performance
  • 11.10.3. Product Benchmarking
  • 11.10.4. Recent Development
• 11.11. Myriad Genetics
  • 11.11.1. Company Overview
  • 11.11.2. Financial Performance
  • 11.11.3. Product Benchmarking
  • 11.11.4. Recent Development
• 11.12. QIAGEN
  • 11.12.1. Company Overview
  • 11.12.2. Financial Performance
  • 11.12.3. Product Benchmarking
  • 11.12.4. Recent Development
• 11.13. Roche Diagnostics
  • 11.13.1. Company Overview
  • 11.13.2. Financial Performance
  • 11.13.3. Product Benchmarking
  • 11.13.4. Recent Development
• 11.14. Sysmex Corporation
  • 11.14.1. Company Overview
  • 11.14.2. Financial Performance
  • 11.14.3. Product Benchmarking
  • 11.14.4. Recent Development
• 11.15. Thermo Fisher Scientific
  • 11.15.1. Company Overview
  • 11.15.2. Financial Performance
  • 11.15.3. Product Benchmarking
  • 11.15.4. Recent Development

List of Tables

• Table 1 Global Oncology Companion Diagnostic Market, by Technology, by Region, 2019-2032 (USD Billion)
• Table 2 Global Oncology Companion Diagnostic Market, by Offering, by Region, 2019-2032 (USD Billion)
• Table 3 Global Oncology Companion Diagnostic Market, by Disease type, by Region, 2019-2032 (USD Billion)
• Table 4 Global Oncology Companion Diagnostic Market, by End User, by Region, 2019-2032 (USD Billion)
• Table 5 Oncology Companion Diagnostic Market Assessment, By Geography, 2019-2032 (USD Billion)
• Table 6 North America: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 7 North America: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 8 North America: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 9 North America: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 10 U.S.: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 11 U.S.: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 12 U.S.: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 13 U.S.: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 14 Canada: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 15 Canada: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 16 Canada: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 17 Canada: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 18 Europe: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 19 Europe: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 20 Europe: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 21 Europe: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 22 Germany: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 23 Germany: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 24 Germany: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 25 Germany: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 26 France: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 27 France: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 28 France: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 29 France: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 30 UK: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 31 UK: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 32 UK: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 33 UK: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 34 Italy: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 35 Italy: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 36 Italy: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 37 Italy: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 38 Netherlands: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 39 Netherlands: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 40 Netherlands: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 41 Netherlands: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 42 Spain: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 43 Spain: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 44 Spain: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 45 Spain: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 46 Russia: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 47 Russia: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 48 Russia: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 49 Russia: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 50 Asia Pacific: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 51 Asia Pacific: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 52 Asia Pacific: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 53 Asia Pacific: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 54 China: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 55 China: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 56 China: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 57 China: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 58 Japan: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 59 Japan: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 60 Japan: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 61 Japan: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 62 India: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 63 India: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 64 India: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 65 India: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 66 Indonesia: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 67 Indonesia: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 68 Indonesia: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 69 Indonesia: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 70 Malaysia: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 71 Malaysia: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 72 Malaysia: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 73 Malaysia: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 74 South Korea: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 75 South Korea: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 76 South Korea: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 77 South Korea: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 78 Latin America: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 79 Latin America: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 80 Latin America: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 81 Latin America: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 82 Brazil: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 83 Brazil: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 84 Brazil: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 85 Brazil: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 86 Mexico: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 87 Mexico: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 88 Mexico: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 89 Mexico: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 90 Argentina: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 91 Argentina: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 92 Argentina: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 93 Argentina: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 94 Middle East & Africa: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 95 Middle East & Africa: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 96 Middle East & Africa: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 97 Middle East & Africa: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 98 UAE: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 99 UAE: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 100 UAE: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 101 UAE: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 102 Saudi Arabia: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 103 Saudi Arabia: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 104 Saudi Arabia: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 105 Saudi Arabia: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 106 South Africa: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 107 South Africa: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 108 South Africa: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 109 South Africa: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
• Table 110 Israel: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
• Table 111 Israel: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
• Table 112 Israel: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
• Table 113 Israel: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)

List of Figures

• Figure 1. Global Oncology Companion Diagnostic Market, 2019-2032 (USD Billion)
• Figure 2. Integrated Ecosystem
• Figure 3. Research Methodology: Top-Down & Bottom-Up End User
• Figure 4. Market by Geography
• Figure 5. Porter's Five Forces
• Figure 6. Market by Technology
• Figure 7. Global Oncology Companion Diagnostic Market, by Technology, 2021 & 2030 (USD Billion)
• Figure 8. Market by End User
• Figure 9. Global Oncology Companion Diagnostic Market, by End User, 2021 & 2030 (USD Billion)
• Figure 10. Market by Offering
• Figure 11. Global Oncology Companion Diagnostic Market, by Offering, 2021 & 2030 (USD Billion)
• Figure 12. Market by Disease type
• Figure 13. Global Oncology Companion Diagnostic Market, by Disease type, 2021 & 2030 (USD Billion)